

## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn20>

### SYNTHESIS OF 5-ETHYNYL-2'-DEOXYURIDINE-5'-BORANOMONO PHOSPHATE AS A POTENTIAL THYMIDYLATE SYNTHASE INHIBITOR

Shoeb I. Khan<sup>a</sup>, Mikhail I. Dobrikov<sup>a</sup> & Barbara Ramsay Shaw<sup>a</sup>

<sup>a</sup> Department of Chemistry, P. M. Gross Chemical Laboratory, Duke University, Durham, North Carolina, USA

Published online: 15 Nov 2011.

To cite this article: Shoeb I. Khan, Mikhail I. Dobrikov & Barbara Ramsay Shaw (2005) SYNTHESIS OF 5-ETHYNYL-2'-DEOXYURIDINE-5'-BORANOMONO PHOSPHATE AS A POTENTIAL THYMIDYLATE SYNTHASE INHIBITOR, *Nucleosides, Nucleotides and Nucleic Acids*, 24:5-7, 1047-1049, DOI: [10.1081/NCN-200060046](https://doi.org/10.1081/NCN-200060046)

To link to this article: <http://dx.doi.org/10.1081/NCN-200060046>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>



## SYNTHESIS OF 5-ETHYNYL-2'-DEOXYURIDINE-5'-BORANOMONO PHOSPHATE AS A POTENTIAL THYMIDYLATE SYNTHASE INHIBITOR

Shoeb I. Khan, Mikhail I. Dobrikov, and Barbara Ramsay Shaw  Department of Chemistry, P. M. Gross Chemical Laboratory, Duke University, Durham, North Carolina, USA

□ The 5-ethynyl-2'-deoxyuridine nucleoside and the 5'-boranomonophosphate nucleotide were synthesized as analogs of 5-fluoro-2'-deoxyuridine monophosphate (5-FdUMP), a widely used mechanism-based inhibitor of thymidylate synthase. Synthesis was carried out from protected 5-iodo-2'-deoxyuridine and trimethylsilylacetylene by Sonogashira palladium-catalyzed cross coupling reaction followed by selective phosphorylation and finally boronation.

**Keywords** Oligonucleotides, Thymidylate Synthase, Boranomonophosphate

### INTRODUCTION


Nucleoside analogs with modifications in the base, sugar, or phosphate residue can be used as probes for substrate properties, kinetic pathways, and transition states of enzymes involved in nucleic acid metabolism. 5-Fluorouracil (FU) and its derivative, 5-fluoro-2'-deoxyuridine monophosphate (5-FdUMP),<sup>[1]</sup> are strong inhibitors of thymidylate synthase (TS), an enzyme responsible for de novo synthesis of DNA thymidine and a major enzyme target for cancer therapeutics. Intrinsic and acquired drug resistance is a limitation of cancer chemotherapy using 5-fluoropyrimidines, which reduce the response rates. It is thus worthwhile to synthesize new analogs and their prodrugs combining the modifications at the phosphate center and C5 pyrimidine position. The substitution of a non-bridging oxygen in a phosphate ester group by a borane (BH<sub>3</sub>) results in a class of phosphate modified nucleotides, e.g., boranomonophosphate.<sup>[2]</sup> Because the BH<sub>3</sub> group is isoelectronic with oxygen and isosteric with a methyl group, it shares a number of chemical and biochemical properties such as good aqueous solubility, increased lipophilicity, and phosphatase resistance. Boranophosphates of nucleosides and

Received 15 October 2004, accepted 19 January 2005.

This research was supported by NIH grant 2RO1-GM57693 to B.R.S.

Address correspondence to Barbara Ramsay Shaw, Department of Chemistry, P. M. Gross Chemical Laboratory, Duke University, Durham, NC 27708, USA; E-mail: brshaw@chem.duke.edu






**SCHEME 1** Synthesis of 5-ethynyl-3'-O-TBDPS-2'-deoxyuridine.

oligonucleotides have recently attracted attention due to their possible therapeutic applications as anticancer and antiviral<sup>[3,4]</sup> prodrugs and antisense agents.<sup>[5]</sup> The aim is to design and synthesize nucleotide prodrugs combining the best nucleoside inhibitors with the advantages of a boranophosphate modification. We hypothesize that nucleoside boranomonophosphates should resist further phosphorylation by nucleoside monophosphate kinase and dephosphorylation by alkaline phosphatase, and thus will increase the effective concentration of the active (monophosphate) drug in the cell.

5-Ethynyl-3'-O-TBDPS-2'-deoxyuridine nucleoside **4** was synthesized following Scheme 1 in 75% yield. Commercially available 5-iodo-2'-deoxyuridine was selectively protected at the 5'- and 3'-hydroxyls by trityl **1** and t-butyldiphenylsilyl **2**, respectively. The palladium mediated cross-coupling reaction was carried out using the Sonogashira method to obtain fully protected nucleoside, which after purification, was treated with sodium methoxide to deprotect the trimethylsilyl group to obtain **3** in 77% yield.

The nucleoside **3** was treated with formic acid and ether to remove the 5'-O-trityl to obtain the 3'-TBDPS protected nucleoside **4** in 75% yield. Finally, nucleoside **4** was phosphorylated by biscyanoethyldiisopropylphosphoramidite using tetrazole in  $\text{CH}_3\text{CN}$  as an activator followed by boronation by borane-dimethylsulfide complex, as shown in Scheme 2 to obtain compound **5** in 71% yield. The 3'-silyl protecting group was removed by TEA:3HF to obtain nucleotide



**SCHEME 2** Synthesis of 5-ethynyl-2'-deoxyuridine-5'-boranomonophosphate.



**6** in 67% yield. Compound **6** on treatment with  $\text{NH}_4\text{OH}/\text{MeOH}$  solution gave 5-ethynyl-2'-deoxyuridine-5'-borano monophosphate **7** in good yield.

In conclusion, of several approaches (not shown) tried to obtain **7**, the approaches described in Schemes 1 and 2 were found to be optimal for synthesis of the 5-ethynyl-2'-deoxyuridine-5'-boranomonophosphate. Biscyanoethyldiisopropylphosphoramidite was the best phosphorylating reagent to obtain the final boranomonophosphate nucleoside **7**.

## REFERENCES

1. Kalman, T.I.; Nie, Z. Rational design of selective antimetabolites of DNA-thymine biosynthesis: 5-propynylpyrimidine nucleoside derivatives. *Nucleosides Nucleotides Nucleic Acids* **2000**, *19*, 357–369.
2. Shaw, B.R.; Dobrikov, M.; Wang, X.; Wan, J.; He, K.; Lin, J.; Li, P.; Rait, V.; Sergueeva, Z.A.; Sergueev, D. Reading, writing, and modulating genetic information with boranophosphate mimics of nucleotides, DNA, and RNA. *Ann. N. Y. Acad. Sci.* **2003**, *1002*, 12–28.
3. Dobrikov, M.; Sergueeva, Z.A.; Shaw, B.R. Incorporation of ( $\alpha$ -P-borano)-2',3'-dideoxycytidine-5-triphosphate into DNA by drug-resistant MMLV reverse transcriptase and *Taq* DNA polymerase. *Nucleosides Nucleotides Nucleic Acids* **2003**, *22*, 1651–1655.
4. Selmi, B.; Boretto, B.; Sarfati, S.R.; Guerreiro, C.; Canard, B. Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an  $\alpha$ -boranophosphate nucleoside analogue. *J. Biol. Chem.* **2001**, *276*, 48466–48472.
5. Wang, X.; Dobrikov, M.; Sergueeva, D.; Shaw, B.R. RNase H activation by stereoregular boranophosphate oligonucleotide. *Nucleosides Nucleotides Nucleic Acids* **2003**, *22*, 1151–1153.